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Medication-Assisted Treatment for Pregnant
Women: A Systematic Review of the Evidence
and Implications for Social Work Practice
Amber M. Holbrook West Chester University
Viba H. Nguyen University of Pennsylvania

Evidence-based practice with pregnant clients who are opioiddependent can be especially challenging because pregnant women are rarely included in clinical trials. The paper synthesizes systematic reviews on the outcomes
of medication-assisted treatment for opioid dependent pregnant women and compares the effectiveness of methadone and buprenorphine. We explore evidence on
maternal and neonatal outcomes, the safety of breastfeeding, and discuss the implications for social work practice. Searches were conducted in 6 databases. Ten
reviews met the inclusion criteria. Results suggest medication-assisted treatment
with either methadone or buprenorphine are equally effective in reducing maternal substance use, although methadone may offer slightly higher treatment retention rates when ﬂexible dosing is implemented. Physical parameters and Apgar
scores at birth show no signiﬁcant differences in neonates exposed to methadone
versus buprenorphine. Rates of treatment for neonatal abstinence syndrome also
do not differ. However, when treatment is required burprenorphine may produce
a shorter duration of withdrawal. Data on long-term developmental outcomes
following in-utero exposure to opioid maintenance medications is inconclusive. Results suggest that there is minimal transmission of either methadone or buprenorphine to the neonate in breast milk. Conclusions are limited by missing data on
broader psychosocial and maternal health outcomes. Evidence on long-term developmental outcomes for neonates is also confounded by prenatal drug exposure and environmental factors. Social workers engage with opioid-dependent pregnant women
in many settings and can play an important role in ensuring access to treatment,
and in addressing misconceptions around medication-assisted treatment for pregnant women with family members, peer supports, and other health care providers.
ABSTRACT
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O

pioid dependence is the fastest growing substance use problem in the
United States, and worldwide one of the most common reasons for seeking addiction treatment (Bart, 2012). Although estimates of the preva-
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lence of opioid dependence during pregnancy are difﬁcult to obtain, an estimated
2 million individuals in the United State abuse or are dependent upon opiates,
including heroin or prescription opiates such as oxycodone and hydrocodone
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2012).
Opiate dependence presents a major public health problem (Degenhardt et al.,
2011; World Health Organization, 2009). As compared with the general population, illicit opiate users—especially injection drug users (IDUs)—have a higher incidence of infectious diseases such as hepatitis, HIV, and tuberculosis (Mathers
et al., 2008; Nelson et al., 2011) and overdose is a signiﬁcant cause of premature
death (Degenhardt et al., 2011). In the United States, deaths related to opiate
analgesic overdose now exceed those caused by heroin and cocaine combined
(Centers for Disease Control and Prevention, 2011). The use of opioids during
pregnancy signiﬁcantly increases rates of preterm birth, spontaneous abortion,
and infant mortality (Park, Meltzer-Brody, & Suzuki, 2012; Shainker, Saia, LeeParritz, 2012), resulting in a six-fold increase in obstetric complications and a 74fold increase in sudden infant death syndrome (Fajemirokun-Odudeyi et al., 2006;
Ludlow, Evans, & Hulse, 2004).
The addiction liability of opiates is high (Bart, 2012), and longer term dependence on opiates can result in chronic alterations in dopaminergic, opioidergic,
and stress responsive pathways, affecting the sensory, emotional, and impulse regulation centers of the brain (Bart, 2012). Medication-assisted treatment is intended
to normalize aspects of stress responsiveness (Bart, 2012), relieve cravings, block the
euphoric effects of illicit opioids, and prevent withdrawal symptoms (Center for Substance Abuse Treatment, 2005). Thus, medication-assisted treatment can be thought
of as relapse prevention in that the medication corrects many of the disrupted neurobiological processes contributing to relapse. In pregnancy, medication-assisted
treatment also serves to stabilize the uterine environment, protecting the fetus from
the stress of repeated withdrawal (Jarvis & Schnoll, 1994). The intended patient
outcomes of medication-assisted treatment with either methadone or buprenorphine are similar to those sought in substance abuse treatment overall: decreased drug use, reduced criminal behavior, and improved social functioning
( Jackson, 2002). For pregnant women, improved maternal and neonatal outcomes
are also a primary goal.
Medication-assisted treatment signiﬁcantly reduces the risk of preterm birth
(Shainker et al., 2012) as well as decreasing the risk of spontaneous abortion
among women using heroin from 10%–20% to 3%–4% (Park, Meltzer-Brody, &
Suzuki, 2012). Infant mortality rates among mothers receiving medication-assisted
treatment are still higher than rates among women who have not used substances
during pregnancy (Shainker et al., 2012). Nonetheless, when compared with outcomes of substance-using women who are not in treatment, it is clear that receipt
of medication-assisted treatment lowers infant mortality rates and promotes fetal
stability (Pritham, Troese, & Stetson, 2007).
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Treatment retention is a strong predictor of long-term substance abuse treatment success, and therefore an important factor to consider in evaluating the
efﬁcacy of treatment (Terplan & Lui, 2007). Medication-assisted treatment is superior to psychosocial interventions alone or detoxiﬁcation both in terms of treatment retention and reduction of substance use (Mattick, Breen, Kimber, & Davoli,
2009; Mayet, Farrell, Ferri, Amato, & Davoli, 2005). A ﬂexible, individualized dosing regimen has been demonstrated to further improve treatment retention for nonpregnant patients (Faggiano, Vigna-Taglianti, Versino, & Lemma, 2003; Mattick,
Breen, Kimber, & Davoli, 2014). However, practitioners often raise concerns that
higher doses of medication-assisted treatment used with pregnant patients might
lead to neonatal abstinence syndrome (NAS), which is a constellation of symptoms
of the gastrointestinal, respiratory, and autonomic and central nervous systems
(Jansson, Velez, & Harrow, 2009). Estimates of the prevalence of NAS range from
48% to 95% in neonates born to mothers receiving opioid maintenance treatment
(Konijnenberg & Melinder, 2011; Winklbaur et al., 2008). Although NAS symptoms
are transitory and do not have long-term effects, extended hospital stays are often
required for treatment of NAS in otherwise healthy infants.
The only two drugs federally approved for medication-assisted therapy for opioid dependence in the United States are methadone and buprenorphine. In the
United States, methadone has been used for more than ﬁve decades, but can be
dispensed only through federally approved opioid treatment programs (OTPs;
SAMHSA, 2013b). In 2002, buprenorphine was approved by the Food and Drug
Administration (FDA) for the treatment of opioid dependence. Physicians must
obtain specialized training to prescribe buprenorphine. Some of these trained
physicians are in private, ofﬁce-based practices, while others are afﬁliated with
substance abuse treatment facilities (SAMHSA, 2013b).
Access to medication-assisted treatment, particularly for pregnant women is
complicated by many persistent barriers, including physical access, cultural norms,
and stigma. Social workers engage with opioid dependent pregnant women in
a variety of service contexts, including criminal justice and health care settings,
through child protective or mental health services, and in outpatient treatment.
Despite this frequent contact, many service providers have an unfavorable perception of OTP treatment:
Unfortunately, many communities and social service providers view OTPs
and their patients with antipathy or disdain. Often, they misunderstand opiate agonist therapy, consider OTPs little more than legalized drug dealers,
and consequently want nothing to do with an agency or its patients. ( Jackson, 2002, p. 24.)
This concern is magniﬁed when the opioid dependent individual is a pregnant
woman (Goddard, 2003). Patients themselves might also be reluctant to seek or
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continue treatment, fearing the disapproval of friends, family, and service providers, or due to fear of unknown medical and developmental consequences for the
fetus (Alto & O’Conner, 2011). As key providers of services to vulnerable and
stigmatized populations, social workers can play a crucial role in facilitating receipt and continuation of treatment for opioid dependent pregnant women.

Present Study
The number of social workers entering the ﬁeld of addictions treatment has increased substantially over the past three decades, making social workers primary
providers of both mental health and addiction services in the United States (National Association of Social Workers, 2014). However, adoption of empirically
supported techniques has been uneven across practice areas, with a slower rate
of implementation noted in the addictions ﬁeld (SAMHSA, 2013a). One of the
key factors in breaking through barriers to implementation of evidence-based
practices in the ﬁeld has been identiﬁed as agency practitioners’ attitudes toward,
and knowledge of, empirically supported approaches (Wolf, Maguin, Ramsey,
& Stringfellow, 2014). Given the concerns and stigma surrounding medicationassisted treatment, social service professionals, clients, and their families often
express a preference for detoxiﬁcation followed by psychosocial treatments to
address opioid dependence during pregnancy. Social workers might be unclear
what outcomes can be expected from medication-assisted treatment, or whether
methadone or buprenorphine is most appropriate for a pregnant client. Therefore, examining the literature on the effectiveness of medication-assisted treatments is particularly important.
Evidence-based practice with pregnant clients who are opioid dependent can
be especially challenging because pregnant women are rarely included in clinical
trials. This means that the current state of knowledge is based largely on case
studies, retrospective chart reviews of women who received treatment, and studies with small sample sizes and no comparison groups ( Johnson, Jones, & Fischer,
2003). Systematic reviews and meta-analyses are one way of sifting and synthesizing this evidence to offer guidance to practitioners. However, although many review articles have been published on the topic of treating opioid dependence during pregnancy, their quality varies widely. In addition, many published reviews
were written with a medical audience in mind rather than a social work audience, and thus focus on the clinical and pharmacological management of the
pregnancy instead of evaluating treatment effectiveness. As Winklbaur et al.
(2008, p. 1430) stated, “Guidance is scarce and published reviews tend to deal
only with one aspect of the patient’s challenges.” The purpose of this paper is to
critically review and synthesize information from the available systematic reviews and meta-analyses on medication-assisted treatment in opioid dependent
pregnant women. Where available, we have examined evidence comparing the
effectiveness of methadone and buprenorphine maintenance. We explore the evi-

This content downloaded from 144.026.046.227 on February 25, 2016 12:36:41 PM
All use subject to University of Chicago Press Terms and Conditions (http://www.journals.uchicago.edu/t-and-c).

Medication-Assisted Treatment During Pregnancy

5

dence available on maternal and neonatal outcomes, the safety of breastfeeding,
and discuss the implication of these ﬁndings for social work practice.

Method
This study is a systematic review of previously published meta-analyses and systematic reviews on the treatment of opioid dependence during pregnancy. We conducted four searches of the PubMed, EMBASE, Cochrane, SocAbs, WorldCat, and
EBSCO databases, using the following sets of key words: (a) methadone, pregnancy;
systematic review; (b) buprenorphine, pregnancy, systematic review; (c) methadone, pregnancy, meta-analysis; and (d) buprenorphine, pregnancy, meta-analysis.
Search range was from January 2000 to August 2013.
The SocAbs, WorldCat, and EBSCO databases returned no results on all four
searches. Results of from the PubMed, EMBASE, and Cochrane databases yielded
158 articles for the ﬁrst set of keywords, 66 articles for the second, 30 articles for
the third, and 13 articles for the fourth set of key words. These results were then
reviewed and edited for duplication, leaving 22 distinct articles, which were then
reviewed for relevance. No articles were excluded on the basis of language criteria, and translations were sought when necessary. Abstracts were reviewed initially and full text was sought when relevance was not clear from the abstract.
We excluded reviews that focused primarily on the effects of illicit drug use,
pharmacological or pain management strategies, or those that did not include
outcomes. Five articles focusing primarily on clinical management strategies
rather than outcomes were excluded based on relevance.
The remaining 17 articles were reviewed for quality and methodological rigor,
using the criteria established by the Cochrane Collaboration and the PRISMA
guidelines. Seven reviews were excluded because the articles did not meet these
criteria (Higgins & Green, 2011; Moher, Liberati, Tetzlaff, Altman, & The PRISMA
Group, 2009). For example, we excluded articles that failed to provide information
on the search criteria used in the review. These exclusions yielded a total of nine
systematic reviews and one meta-analysis that were included in our review.

Results
The majority of the systematic reviews meeting the inclusion criteria focused on
neonatal rather than maternal outcomes of medication-assisted treatment. Two
reviews examined maternal outcomes of treatment retention and concomitant
substance use, whereas three reviews examined breastfeeding safety evidence and
outcomes. Among the eight reviews addressing neonatal outcomes, the majority
of the focus was on the length and severity of NAS symptoms. This limited scope
indicates that although key outcomes have been addressed, data on many important
maternal and neonatal outcomes might still be limited. In addition, most systematic
reviews available on medication-assisted treatment during pregnancy did not provide concrete data on effect sizes, p values, or conﬁdence intervals for the ﬁndings.
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Maternal Outcomes
Two of the systematic reviews included maternal outcomes, with a focus on concomitant substance use and treatment retention (Minozzi, Amato, Vecchi, & Davoli,
2013; Winklbaur et al., 2008). However, these reviews did not examine other important indicators of psychosocial functioning and health risk, such as engagement
in criminal activity, transmission of infectious diseases, or compliance with prenatal care.
Substance use. Methadone and buprenorphine appear to be equally efﬁcacious in
reducing use of opioids during pregnancy (RR 1.81, 95% CI [0.70, 4.69]; Minozzi et al.,
2013; Winklbaur et al., 2008). This efﬁcacy appears to increase when medicationassisted treatment uses a ﬂexible dosing regimen that is not capped at a lower dosage (Mattick et al., 2014).
Treatment retention. Although one of the two studies examining maternal outcomes reported no differences in treatment retention between pregnant patients
maintained on methadone versus those maintained on buprenorphine (Winklbaur
et al., 2008), evidence from the remaining study suggested that when ﬂexible
dosing was implemented, maintenance with methadone achieved slightly better
retention rates (RR 0.64, 95% CI [0.41, 1.01] (Minozzi et al., 2013).

Neonatal Outcomes
Preterm birth and infant mortality. Currently, only limited evidence is available
comparing the effects of methadone with the effects of buprenorphine on improving rates of preterm birth, spontaneous abortion, and infant mortality (Minozzi
et al., 2013).
Apgar scores. The Apgar test is a brief assessment of an infant’s breathing, heart
rate, muscle tone, reﬂexes, and skin color performed at 1 minute and 5 minutes
after birth to assess how well the infant tolerated the birth process and how well
the infant is doing outside the womb. Only Minozzi et al. (2013) examined scores
on the Apgar test, and their review reported no signiﬁcant differences between
infants whose mothers who received methadone during pregnancy and those who
had received buprenorphine (MD 0.00, 95% CI [0.03, 0.03]).
Birth weight and head circumference. Three of the included reviews examined
infant head circumference (Bandstra, Morrow, Mansoor, & Accornero, 2010; Goodman, 2011; Konijnenberg & Melinder, 2011), and four analyzed the available
evidence on birth weight (Bandstra et al., 2010, Goodman, 2011; Konijnenberg &
Melinder, 2011; Minozzi et al., 2013). All four reviews noted a scarcity of studies reporting on these neonatal outcomes, as well as the failure of the available
studies to control for maternal nicotine use, which is a signiﬁcant confounding
factor for low birth weight.
The results suggested that infants exposed to opiates exhibit signiﬁcantly lower
birth weights and head circumferences as compared with their counterparts who
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were not exposed to opiates during gestation (Konijnenberg & Melinder, 2011).
Receipt of maternal substance abuse treatment was correlated with higher birth
weights in, opioid-exposed infants when compared to infants born to women not
receiving treatment (Bandstra et al., 2010). Overall, medication-assisted treatment
was shown to increase the duration of gestation, birth weight, and head circumference of opioid-exposed infants with no signiﬁcant differences found between
the beneﬁts of methadone versus buprenorphine (mean difference [MD] −365.45 g,
95% CI [−673.84, −57.07]; Goodman, 2011; Minozzi et al., 2013;).
Neonatal abstinence syndrome. Although one large-scale clinical trial ( Jones
et al., 2010), and one systematic review ( Johnson et al., 2003) reported lower rates
of NAS treatment with buprenorphine versus methadone other studies found no
difference in incidence of NAS between the two medications (Welle-Strand et al.,
2013). The systematic review conducted by Minozzi et al. (2013) found methadone
and buprenorphine did not differ in the rate of NAS resulting from maternal
treatment (RR 1.22, 95% CI [0.89, 1.67]); however, the authors did ﬁnd that maternal treatment with buprenorphine not only resulted in shorter duration of infant
treatment for NAS, when required (MD 4.01, 95% CI [1.29, 9.30]) but also necessitated a lower total dose of morphine to control symptoms in the neonate (MD 5.06,
95% CI [−3.36, 13.47]). A recent meta-analysis and systematic review also suggested
that neither average prenatal dose nor maternal methadone dose at delivery were
correlated with the emergence of NAS in the neonate (Cleary et al., 2010; Thajam,
Atkinson, Sibley, & Lavender, 2010). No evidence was found in the literature on
the impact of buprenorphine dosage during pregnancy on the rates or severity of
NAS.
Long-term developmental outcomes. Limited data were found on the long-term
developmental outcomes of children who were exposed to methadone or buprenorphine in utero, with only one systematic review meeting the criteria for inclusion. The few longitudinal studies available on human subjects have offered
conﬂicting results regarding cognitive development and performance, with some
reporting no differences between opiate-exposed and non-exposed children and
others ﬁnding lower cognitive performance among opiate-exposed children (i.e.,
exposed to either methadone or buprenorphine; Konijnenberg & Melinder, 2011).
When differences were noted between exposed and non-exposed children, such
differences were observed in cognitive and language functions, but not in nonverbal performance (i.e., motor skills and sensory) tasks as evidenced by scores on
the Bayley Scales of Infant and Toddler Development and Stanford-Binet Intelligence Scale (Konijnenberg & Melinder, 2011).
Breastfeeding. Three reviews examining the outcomes for breastfeeding with
either methadone or buprenorphine maintenance met the inclusion criteria. Although several studies have examined the transmission of methadone in breast
milk and found minimal levels of the drug ( Jansson, Velez, & Harrow, 2004),
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all studies to date appear to have used small sample sizes (Muller, Lange, Paul, &
Seeliger, 2011). Further, the existing literature examining the transmission of buprenorphine to the neonate via breast milk primarily consists of case reports. The
limited pharmacologic data available suggest that low oral bioavailability of buprenorphine contained in breast milk may minimize potential effects on the neonate (Goodman, 2011).

Discussion
Our results suggest that once ﬂexible dosing is implemented in medicationassisted treatment during pregnancy, both methadone and buprenorphine offer
similar results with regards to reduction of substance use; however, better treatment retention might be achieved with methadone. This ﬁnding is consistent
with the literature on non-pregnant substance use patients among whom greater
treatment attrition is noted in patients receiving buprenorphine, but both medications are found equally effective in reducing opioid and other illicit drug use
(Mattick et al., 2014).
Our review noted a lack of evidence for the efﬁcacy of medication-assisted
treatment on a broader range of indicators of psychosocial functioning and maternal health outcomes. Although the receipt of medication-assisted treatment is
widely thought to improve both the rate of transmission of infectious diseases
and compliance with prenatal care (Carrieri et al., 2006; Roberts, 2011; Ruger &
Lazar, 2012), we did not ﬁnd any studies addressing these outcomes. Moreover,
none of the studies included in this review measured reductions in criminal
activity even though criminal activity has been shown to be substantially reduced
in non-pregnant patients receiving either methadone or buprenorphine treatment
for opioid dependence (Faggiano et al., 2008; Mattick et al., 2014). None of the
included reviews examined the impact of treatment on relationship quality or
parenting.
The limited evidence available suggests that methadone and buprenorphine
have similar effects on Apgar scores, head circumference, and birth weight. Birth
weight and head circumference are considered important indicators of fetal development, predictors of newborn well-being, and etiological indicators that determine the need for additional surveillance of newborn health. Birth weight is
associated with infant mortality during the ﬁrst year of life and provides an estimate of the rate of small-for-gestational age and preterm births in a population
(Wilcox, 2001). Head circumference is used by pediatricians an indicator of brain
size and growth. The mechanism by which medication-assisted treatment achieves
these outcomes is not clear, but researchers have posited the medication-assisted
treatment yields positive outcomes through the stabilization of the uterine environment, improved nutrition, consistent receipt of prenatal care, and/or reduction
in rates of preterm births (Fajemirokun-Odudeyi et al., 2006; Ludlow et al., 2004).
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Although some research has suggested buprenorphine offers reduced incidence
of NAS ( Jones et al., 2010; Winklbaur et al., 2008), similar rates of treatment for
NAS were found among neonates exposed to methadone and buprenorphine in
utero. However, our ﬁndings suggest that, when treatment for NAS is required,
infants exposed to buprenorphine may require a shorter duration of treatment.
The evidence found on the safety of breastfeeding during medication-assisted
treatment was limited, but suggests that only low levels of either methadone or
buprenorphine are transmitted to infants through breast milk. Breastfeeding has
been associated with signiﬁcant beneﬁts in the form of superior infant nutrition,
improved immunity, promotion of mother-infant bonding, and support of the
infant’s cognitive development (Hilton, 2012; Ip et al., 2007). Given the risk of
poor health and developmental trajectories for children exposed to abused drugs
in utero (Behnke et al., 2013), and the challenges in mother-infant attachment
that often occur in this population, the beneﬁts that breastfeeding might provide are considerable (Glatstein, Garcia-Bournissen, Finkelstein, & Koren, 2008).
On the other hand, little is known regarding the transmission of opioid maintenance medication via breast milk or its potential effects on the neonate. In addition, breastfeeding may be complicated by a number of factors. Symptoms of
NAS, such as nasal stufﬁness, irritability, hypertonicity, and an uncoordinated sucking response can interfere with the infant’s ability to nurse easily (Jannson et al.,
2004). The mother of an infant who is hospitalized for NAS treatment for an
extended length of time might ﬁnd it difﬁcult to visit their treatment provider
daily, care for other children, and visit the neonate multiple times per day for
feeding. Despite these challenges, the American Academy of Pediatrics has recommended that mothers maintained on either methadone or buprenorphine
should be encouraged to breastfeed their infants (Hilton, 2012), provided no other
contraindications are present, such as continued concomitant drug abuse, HIV
positivity, or maternal use of certain prescribed psychotropic medications. Notably, hepatitis C infection is not necessarily a contraindication if a woman wishes
to breastfeed (Winklbaur et al., 2008).

Future Directions for Research
Although researchers have conducted numerous reviews of medication-assisted
treatment during pregnancy, the majority of these reviews have focused on clinical management of the pregnancy rather than the effect of treatment on substance use, treatment retention, delivery complications, and transmission of infectious disease. In addition, a number of methodological concerns pose serious
limitations regarding the evidence on maternal outcomes for methadone and buprenorphine, including infrequent inclusion of pregnant women in clinical trials,
small sample sizes, and failure to control for concomitant substance use. Substantial differences in methodology have also prevented the synthesis of results across
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studies (Winklbaur et al., 2008). Even though it is clear that medication-assisted
treatment offers improved outcomes over detoxiﬁcation or behavioral interventions alone, more research is needed on the role of ﬂexible dosing regimens in
improving treatment retention and reducing concomitant substance use.
The majority of reviews on neonatal outcomes of medication-assisted treatment have focused on the occurrence and severity of NAS. Many of the studies
included in the systematic reviews did not control for confounding factors such as
maternal nicotine use or the use of psychotropic medications. Failure to account
for the impact of maternal nicotine use is a signiﬁcant oversight because approximately 90% of opioid dependent women are also heavy smokers (Winklbaur et al.,
2008). Given that a large number of substance abusing women also have cooccurring psychiatric disorders for which they require treatment (Fitzsimmons,
Tuten, Vaidya, & Jones, 2007), it is critically important that studies control for
maternal use of psychotropic medications, particularly benzodiazepines and serotonin selective reuptake inhibitors (SSRIs) that are used in the treatment of anxiety
and depression. Moreover, symptoms of NAS can be mimicked by an infant’s
withdrawal from nicotine (Kaltenbach et al., 2012; Winklbaur et al., 2009), benzodiazepines (Prithim et al., 2007; Welle-Strand et al., 2013), and SSRIS (Kaltenbach
et al., 2012), and withdrawal from these substances can impacting a broad range
of other neonatal outcomes as well (Lattimore et al., 2005; Winklbaur et al., 2008).
Although NAS is a signiﬁcant issue that impacts health care costs and the quality
of mother-infant bonding, it is important to note that NAS is transitory and does
not have long-term effects on neonatal health and developmental outcomes. Further studies that address a broader range of neonatal outcomes are much needed.
Studies on long-term developmental outcomes are constrained by a number of
methodological issues, including small sample sizes, failure to control for environmental factors, and poorly deﬁned comparison groups (Bandstra et al., 2010).
Current researchers in this area have found it especially difﬁcult to delineate the
effects of illicit prenatal drug exposure and the home environment on the developing child from the longer term effects of prenatal maintenance treatment.
Issues of dosage and timing of exposure during pregnancy have yet to be explored. Integration of the animal and human research on opioid exposure have
suggested several potential pathways by which opiate maintenance treatment
might affect cognitive development, including fetal growth and maturity, myelination, endocrine function, and/or neurotransmitter content (Konijnenberg &
Melinder, 2011).

Implications for Social Work Practice
Treatment for opiate addiction requires a long-term, comprehensive treatment
approach. To date, no studies have supported the effectiveness of setting a ﬁxed
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limit on the duration of treatment (Minozzi et al., 2013). The recommended approach to medication-assisted treatment for pregnant women is to combine ﬂexible dosing with individualized treatment plans that address ﬁnancial, psychological, medical, legal, and social concerns (Winklbaur et al., 2008). In addition,
treatment programs that include more frequent counseling contact and use of
contingency management strategies, such as tying increased privileges to urinalysis results, might assist in reducing use of other drugs that are frequently abused
by this population such as cannabis, cocaine, and benzodiazepines (Winklbaur
et al., 2008).
Given that social workers are the main providers of substance abuse, mental
health, and child welfare services in the United States, social workers are likely to
encounter pregnant and parenting women who are opioid dependent in multiple
settings. It is important that social workers offer these women accurate information on seeking treatment for opioid dependence, encourage them to access the
full dose required for stabilization, and support informed decision making about
breastfeeding. Many opioid-dependent women experience stigma and confront
prejudice regarding medication-assisted treatment from their family members,
hospital nursing staff, other social service providers, and even 12-step programs.
Furthermore, if these women are recently released inmates, they are at particularly high risk for overdose and disease transmission (Rich, McKenzie et al., 2005).
By providing women returning to the community with links to methadone treatment immediately upon release from incarceration, social workers have an opportunity to combat disease transmission, facilitate reentry into the community,
and reduce recidivism (Rich, Boutwell, et al., 2005; Rich, McKenzie et al., 2005);
however, this opportunity is frequently overlooked or neglected (Nunn et al.,
2009). Social workers in correctional settings and community organizations that
serve returning citizens could play a more active role in bridging gaps between
criminal justice agencies and substance abuse facilities that offer medicationassisted treatment.
Social workers can also play a role in educating family members regarding
the beneﬁts of medication-assisted treatment as well as the commitment and
support required for successful, long-term recovery. Facilitating family education
groups can offer family members the opportunity to ask important questions
about medication-assisted treatment, the recovery process, and long-term effects
of drug use and medication-assisted treatment on the neonate. Family education
groups can help repair and strengthen social supports that are critical for the
mother’s successful recovery.
Local 12-step groups can also play an important role in fostering recovery. Unfortunately, the culture of some 12-step meetings can be resistant to medicationassisted treatment for opioid-dependent individuals. Consequently, social workers
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in substance abuse treatment programs can help to ensure a meeting climate in
which opioid-dependent women will feel supported by partnering with a peer specialist and reaching out to 12-step groups to create a dialogue around medicationassisted treatment. Another way social workers can assist in building support in
the community is through providing technical and organizational support to individuals wishing to organize a local Methadone Anonymous group in areas where
such groups are not available.
Nursing staff in obstetric/gynecological clinics and neonatal hospital units who
are unfamiliar with the evidence supporting medication-assisted treatment for
pregnant opioid-dependent women might have reservations about particular aspects of the treatment. Nurses might be worried that the higher doses of methadone or buprenorphine during pregnancy will lead to poor neonatal outcomes,
particularly a higher incidence and severity of NAS. In addition, poorly informed
nursing staff might discourage breastfeeding in women receiving medicationassisted treatment out of concern for the impact of the medication on the neonate,
or because they have reservations regarding other substances (such as nicotine or
illicit drugs) that the patient might use. Multiple barriers to successful breastfeeding may occur, ranging from active discouragement by neonatal nursing staff to
the physical symptoms of NAS that make breastfeeding challenging. Inclusion of
social workers in the treatment planning process can help in addressing some
of these issues. Social workers in health care settings can assist with counseling
patients to alleviate fears of dose increases, and provide balanced information
regarding the beneﬁts and risks of breastfeeding for each patient. Social workers
can also offer nonjudgmental information on the impact of nicotine use and the
use of illicit drugs, especially benzodiazepines, on the neonate, and help to ensure the woman has the psychosocial supports needed for recovery and to pursue
breastfeeding if she chooses.

Conclusion
Long-term medication-assisted treatment for opioid-dependent pregnant women
has the potential to improve both immediate and long-term maternal and neonatal outcomes. Data on the safety of breastfeeding remains limited, but the available evidence suggests that transmission of methadone or buprenorphine to the
neonate via breast milk is minimal. It is critically important that social workers
provide direct support to opioid-dependent pregnant women in a variety of settings, as well as engage in advocacy and community education around the broad
range of beneﬁts that can be offered by medication-assisted treatment. Given that
social workers are keenly concerned with social determinants of health and combating stigmatization that can function to reduce access to care, these professionals are positioned to play a leadership role in disseminating the evidence regarding the beneﬁts to mother and child offered by medication-assisted treatment.
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